CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
-1.39%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$345M
AUM Growth
+$21M
(+6.5%)
Cap. Flow
+$33M
Cap. Flow
% of AUM
9.58%
Top 10 Holdings %
Top 10 Hldgs %
32.78%
Holding
466
New
14
Increased
365
Reduced
39
Closed
20
Top Buys
| 1 |
Amazon
AMZN
|
$3.98M |
| 2 |
Procter & Gamble
PG
|
$3.03M |
| 3 |
Booking.com
BKNG
|
$2.86M |
| 4 |
Apple
AAPL
|
$2.77M |
| 5 |
SPDR Gold MiniShares Trust
GLDM
|
$2.63M |
Top Sells
| 1 |
NVIDIA
NVDA
|
$3.25M |
| 2 |
TSMC
TSM
|
$3.11M |
| 3 |
Carnival Corp
CCL
|
$2.64M |
| 4 |
On Holding
ONON
|
$2.57M |
| 5 |
Advanced Micro Devices
AMD
|
$2.07M |
Sector Composition
| 1 | Technology | 38.24% |
| 2 | Consumer Discretionary | 20.57% |
| 3 | Healthcare | 19.52% |
| 4 | Communication Services | 8.19% |
| 5 | Consumer Staples | 3.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ADAP
401
Adaptimmune Therapeutics
ADAP
$13.5M
| $4.12K | ﹤0.01% |
5,285
+3,367
| +176% | +$2.63K |
|
|
GRTS
402
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $4.11K | ﹤0.01% |
2,392
+1,226
| +105% | +$2.11K |
|
403
Mersana Therapeutics
MRSN
$35.5M
| $3.93K | ﹤0.01% |
124
+64
| +107% | +$2.03K |
|
404
Karyopharm Therapeutics
KPTI
$58.4M
| $3.93K | ﹤0.01% |
195
+95
| +95% | +$1.91K |
|
405
Atara Biotherapeutics
ATRA
$89.9M
| $3.83K | ﹤0.01% |
104
+53
| +104% | +$1.95K |
|
|
LENZ
406
LENZ Therapeutics
LENZ
$1.14B
| $3.68K | ﹤0.01% |
212
+103
| +94% | +$1.79K |
|
|
OPTN
407
DELISTED
OptiNose
OPTN
| $3.54K | ﹤0.01% |
192
+94
| +96% | +$1.73K |
|
408
Altimmune
ALT
$314M
| $3.52K | ﹤0.01% |
1,354
+708
| +110% | +$1.84K |
|
409
Design Therapeutics
DSGN
$348M
| $3.39K | ﹤0.01% |
1,435
+702
| +96% | +$1.66K |
|
410
Codexis
CDXS
$218M
| $3.38K | ﹤0.01% |
1,790
+915
| +105% | +$1.73K |
|
411
Prelude Therapeutics
PRLD
$64.5M
| $3.33K | ﹤0.01% |
1,076
+389
| +57% | +$1.2K |
|
412
Annexon
ANNX
$236M
| $3.23K | ﹤0.01% |
1,368
+673
| +97% | +$1.59K |
|
413
Absci
ABSI
$359M
| $3.15K | ﹤0.01% |
2,383
+1,171
| +97% | +$1.55K |
|
414
PepGen
PEPG
$42M
| $3.12K | ﹤0.01% |
615
+304
| +98% | +$1.54K |
|
415
Century Therapeutics
IPSC
$41.4M
| $3.06K | ﹤0.01% |
1,528
+747
| +96% | +$1.49K |
|
|
OMGA
416
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $3.04K | ﹤0.01% |
1,414
+693
| +96% | +$1.49K |
|
417
Nektar Therapeutics
NKTR
$684M
| $2.91K | ﹤0.01% |
325
+160
| +97% | +$1.43K |
|
|
NIU
418
Niu Technologies
NIU
$335M
| $2.83K | ﹤0.01% |
1,000
| – | – |
|
419
TAL Education Group
TAL
$6.24B
| $2.73K | ﹤0.01% |
300
+200
| +200% | +$1.82K |
|
420
Sangamo Therapeutics
SGMO
$160M
| $2.73K | ﹤0.01% |
4,546
+2,294
| +102% | +$1.38K |
|
421
Esperion Therapeutics
ESPR
$510M
| $2.69K | ﹤0.01% |
2,748
+1,507
| +121% | +$1.48K |
|
422
Kroger
KR
$44.9B
| $2.69K | ﹤0.01% |
60
-5,500
| -99% | -$246K |
|
423
Inovio Pharmaceuticals
INO
$146M
| $2.68K | ﹤0.01% |
574
+287
| +100% | +$1.34K |
|
424
Kodiak Sciences
KOD
$452M
| $2.43K | ﹤0.01% |
1,349
+663
| +97% | +$1.19K |
|
|
IMAB
425
I-MAB
IMAB
$355M
| $2.36K | ﹤0.01% |
1,789
+886
| +98% | +$1.17K |
|